Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias
暂无分享,去创建一个
W. Crumb | J. Guillon | I Cavero | M Mestre | J M Guillon | W Crumb | I. Cavero | M. Mestre
[1] P. Kuo,et al. Cardiac Electrophysiology: From Cell to Bedside , 1991 .
[2] D. Wysowski,et al. Cisapride and fatal arrhythmia. , 1996, The New England journal of medicine.
[3] C. Hoe,et al. The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.
[4] M. Malik,et al. Comparison of Formulae for Heart Rate Correction of QT Interval in Exercise Electrocardiograms , 1999, Pacing and clinical electrophysiology : PACE.
[5] R. Hauer,et al. Genetic and molecular basis of cardiac arrhythmias : Impact on clinical management , 1999 .
[6] H. Crijns,et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine , 1999, The Lancet.
[7] D. Clapham,et al. Ion channels--basic science and clinical disease. , 1997, The New England journal of medicine.
[8] S. H. Thomas,et al. Drugs, QT interval abnormalities and ventricular arrhythmias. , 1994, Adverse drug reactions and toxicological reviews.
[9] G. Tomaselli,et al. Electrophysiological remodeling in hypertrophy and heart failure. , 1999, Cardiovascular research.
[10] D. Roden,et al. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.
[11] J. Brugada,et al. RP 58866 and Its Active Enantiomer RP 62719 (Terikalant): Blockers of the Inward Rectifier K+ Current Acting as Pure Class III Antiarrhythmic Agents , 1992, Journal of cardiovascular pharmacology.
[12] I. Gussak,et al. Naming of the waves in the ECG, with a brief account of their genesis. , 1998, Circulation.
[13] B. Surawicz. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? , 1989, Journal of the American College of Cardiology.
[14] C. Lathers,et al. Cardiac Arrhythmia, Sudden Death, and Psychoactive Agents , 1987, Journal of clinical pharmacology.
[15] A. Markham,et al. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. , 1999, Drugs.
[16] S. Priori,et al. Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias , 2000, Journal of cardiovascular electrophysiology.
[17] S. Priori. Exploring the Hidden Danger of Noncardiac Drugs , 1998, Journal of cardiovascular electrophysiology.
[18] J. Weiss,et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. , 1996, Journal of the American College of Cardiology.
[19] Cavero,et al. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.
[20] Hurst Jw. Naming of the Waves in the ECG, With a Brief Account of Their Genesis , 1998 .
[21] P. Coumel,et al. Changes in Repolarization Dynamicity and the Assessment of the Arrhythmic Risk , 1997, Pacing and clinical electrophysiology : PACE.
[22] I. Ovsyshcher. Torsades de pointes. , 1988, American heart journal.
[23] Electrophysiological effects of LU111995 on canine hearts: in vivo and in vitro studies. , 1999, The Journal of pharmacology and experimental therapeutics.
[24] S. Hohnloser,et al. Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.
[25] D. Levy,et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) , 1992, The American journal of cardiology.
[26] J. Ruskin,et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. , 1996, American heart journal.
[27] H. Wellens,et al. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. , 1995, Circulation.
[28] E. Williams. Significance of Classifying Antiarrhythmic Actions Since the Cardiac Arrhythmia Suppression Trial , 1991 .
[29] C. Pratt,et al. Cardiovascular safety of fexofenadine HCl. , 1999, The American journal of cardiology.
[30] H. Kennedy,et al. Torsades de pointes associated with drugs and toxins: recognition and management. , 1987, American heart journal.
[31] C. Moorehead. All rights reserved , 1997 .
[32] S. Viskin. Long QT syndromes and torsade de pointes , 1999, The Lancet.
[33] E. V. Vaughan Williams. Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. , 1991, Journal of clinical pharmacology.
[34] C. January,et al. Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.
[35] A. S. Davis. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods , 1998, Human & experimental toxicology.
[36] F. Ponti,et al. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.
[37] S. Giampaoli,et al. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: emphasis on the cubic root Fridericia's equation. , 1988, Journal of electrocardiology.
[38] A. Brown,et al. Blockade of HERG and Kv1.5 by ketoconazole. , 1998, The Journal of pharmacology and experimental therapeutics.
[39] A. Roses,et al. Pharmacogenetics and future drug development and delivery , 2000, The Lancet.
[40] A J Camm,et al. Arrhythmogenic mechanisms of non‐sedating antihistamines , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[41] D. Escande,et al. Steady‐State versus Non‐Steady‐State QT‐RR Relationships in 24‐hour Holter Recordings , 2000, Pacing and clinical electrophysiology : PACE.
[42] A. Moss. Drugs that Prolong the QT Interval: Regulatory and QT Measurement Issues from the United States and European Perspectives , 1999 .
[43] W. Allan,et al. The long-QT syndrome. , 2000, The New England journal of medicine.
[44] R. Woosley,et al. Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.
[45] A. Brown,et al. Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.
[46] J. Robinson. Prinzmetal's variant angina pectoris. Report of a case. , 1965, American heart journal.
[47] R. Fenichel. Development of Drugs That Alter Ventricular Repolarization , 2002, American journal of therapeutics.
[48] A. Katz,et al. Selectivity and toxicity of antiarrhythmic drugs: molecular interactions with ion channels. , 1998, The American journal of medicine.
[49] C. Pratt,et al. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. , 1994, The American journal of cardiology.
[50] B. Drolet,et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. , 1999, The Journal of pharmacology and experimental therapeutics.
[51] K. Hartigan-Go,et al. Stereoselective cardiotoxic effects of terodiline , 1996, Clinical pharmacology and therapeutics.
[52] D. Mark,et al. Fundamentals of economic analysis , 1999 .
[53] R. Porsolt,et al. QT interval prolongation by noncardiovascular drugs: A proposed assessment strategy , 1999 .
[54] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[55] P. Bennett. Anchors Aweigh!: ion channels, cytoskeletal proteins, and cellular excitability. , 2000, Circulation research.
[56] C. January,et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.
[57] M. Malik. QT dispersion: time for an obituary? , 2000, European heart journal.
[58] G. Talbot,et al. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. , 1996, The Journal of antimicrobial chemotherapy.
[59] P Jaillon,et al. Rate-corrected QT interval: techniques and limitations. , 1993, The American journal of cardiology.
[60] P. Coumel,et al. Dispersion of ventricular repolarization: reality? Illusion? Significance? , 1998, Circulation.
[61] T. Denton,et al. Comprehensive electrocardiology : theory and practice in health and disease , 1990 .
[62] J. Davy,et al. Experimental models of torsades de pointes , 1992, Fundamental & clinical pharmacology.
[63] S. Nattel,et al. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. , 1990, The American journal of medicine.
[64] M Kawataki,et al. Relation between QT interval and heart rate. applications and limitations of Bazett's formula. , 1984, Journal of electrocardiology.
[65] D. Roden,et al. Cisapride‐Induced Torsades de Pointes , 1998, Journal of cardiovascular electrophysiology.
[66] B. Surawicz,et al. Ventricular arrhythmias: why is it so difficult to find a pharmacologic cure? , 1989, Journal of the American College of Cardiology.
[67] S. Nightingale,et al. From the Food and Drug administration. , 1990, JAMA.
[68] M. Keating,et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.
[69] S. Priori,et al. Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.
[70] D. Roden. Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.
[71] Joel Morganroth,et al. How to Obtain and Analyze Electrocardiograms in Clinical Trials , 1999 .
[72] G. Breithardt,et al. Experimental models of torsade de pointes. , 1998, Cardiovascular research.
[73] L. Guize,et al. Measurement of QT Interval , 1997 .
[74] F. D. de Abajo,et al. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. , 1999, British journal of clinical pharmacology.
[75] P. Coumel,et al. Dynamic analysis of dofetilide‐induced changes in ventricular repolarization , 1998, Clinical pharmacology and therapeutics.
[76] Y Chen,et al. Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.
[77] H. Karagueuzian,et al. Idiopathic Paroxysmal Atrial Fibrillation Induced by a Focal Discharge Mechanism in the Left Superior Pulmonary Vein: , 1999, Journal of cardiovascular electrophysiology.
[78] Focus on issues in measuring and interpreting changes in the QTc interval duration , 2001 .
[79] Morrison Hodges,et al. Rate Correction of the QT Interval , 1997 .
[80] P. Coumel,et al. Physiology of QT Interval Dynamicity , 1997 .